phosphate(3-)What was measured
Measured, with no finding
318 endpoints
Show what was measuredHide what was measured
serum Ca, PO4, Zn, 1,25-(OH)2D3 and urinary beta-2-microglobulin
no effect, n = 10
There were no changes in serum levels of Ca, PO4 or Zn, in serum concentration of 1,25-(OH)2D3, and in urinary beta-2-microglobulin excretion
PMID 11305263 · one of two readings recorded this
serum osteocalcin
no effect, n = 10
a decrease of 0.6+/-0.6 ng/ml in serum osteocalcin
PMID 11305263 · one of two readings recorded this
serum PTH
no effect, n = 10
an increase of 10.7+/-13.7 pg/ml in serum PTH
PMID 11305263 · one of two readings recorded this
urinary deoxypyridinoline
no effect, n = 10
of 19.3+/-36.0 nmol/ mmol creatinine in urinary deoxypyridinoline
PMID 11305263 · one of two readings recorded this
urinary microalbumin
no effect, n = 10
a decrease of 2.6+/-9.3 mg/l in urinary microalbumin
PMID 11305263 · one of two readings recorded this
urinary pyridinoline
no effect, n = 10
an increase of 73.6+/-136.6 nmol/mmol creatinine in urinary pyridinoline
PMID 11305263 · one of two readings recorded this
serum 1,25-dihydroxycholecalciferol
no effect
serum 1,25-dihydroxycholecalciferol remained unchanged
PMID 1422972 · one of two readings recorded this
serum bone alkaline phosphatase
no effect
no significant changes were observed in urinary hydroxyproline/creatinine ratio, or serum bone alkaline phosphatase
PMID 1422972 · one of two readings recorded this
serum calcium
no effect
no significant changes were seen in serum phosphate or serum calcium
PMID 1422972 · one of two readings recorded this
serum osteocalcin (mean)
increases, p = 0.05
In the group receiving 1500 mg/day, mean serum osteocalcin was increased in the period from day 1 to day 28 (P less than 0.05)
PMID 1422972 · one of two readings recorded this
serum osteocalcin
no effect
Furthermore, 1500 mg/day but not 2250 mg/day increases serum osteocalcin
PMID 1422972 · one of two readings recorded this
serum parathyroid hormone (PTH)(1-84) during oral phosphate treatment
increases, rose to a maximum of 36 and 33% in the 1500 and 2250 mg/day groups
Not recorded as a finding: this platform holds no node for the endpoint
Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively, whereas serum 1,25-dihydroxycholecalciferol remained unchanged.
PMID 1422972 · one of two readings recorded this
serum parathyroid hormone (PTH) maximum rise
increases, p = 0.05
Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively
PMID 1422972 · one of two readings recorded this
serum parathyroid hormone (PTH) maximum rise
increases, p = 0.05
Serum parathyroid hormone (PTH) rose significantly (P less than 0.05) during treatment to a maximum of 36 and 33% in the groups receiving 1500 and 2250 mg/day, respectively
PMID 1422972 · one of two readings recorded this
serum phosphate, assay not stated in the abstract
no effect
Not recorded as a finding: the paper never states the instrument the node requires
Urinary phosphate/creatinine ratio increased in a dose-dependent fashion during treatment (P less than 0.001), whereas no significant changes were seen in serum phosphate or serum calcium.
PMID 1422972 · one of two readings recorded this
serum phosphate
no effect
no significant changes were seen in serum phosphate or serum calcium
PMID 1422972 · one of two readings recorded this
urinary hydroxyproline/creatinine ratio
no effect
no significant changes were observed in urinary hydroxyproline/creatinine ratio, or serum bone alkaline phosphatase
PMID 1422972 · one of two readings recorded this
urinary phosphate/creatinine ratio
increases, p = 0.001
Urinary phosphate/creatinine ratio increased in a dose-dependent fashion during treatment (P less than 0.001)
PMID 1422972 · one of two readings recorded this
urine acidification over the monitored period
no effect, n = 7
In addition, urine acidification was not achieved over the time period when urine pH was monitored
PMID 15570319 · one of two readings recorded this
urine pH measured three times a day (first morning, afternoon, evening samples) in patients with neurogenic bladder on clean intermittent catheterization, on versus off a phosphorus supplement
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There was no significant change in urine pH during the 2-week period when a patient was on phosphorus supplementation compared to when the patient was off supplementation.
PMID 15570319 · one of two readings recorded this
urine pH measured three times a day in patients with neurogenic bladder on clean intermittent catheterization, on versus off a phosphorus supplement
no effect
Not recorded as a finding: this platform holds no node for the endpoint
There was no significant change in urine pH during the 2-week period when a patient was on phosphorus supplementation compared to when the patient was off supplementation.
PMID 15570319 · one of two readings recorded this
urine pH
no effect, n = 7
There was no significant change in urine pH during the 2-week period when a patient was on phosphorus supplementation compared to when the patient was off supplementation
PMID 15570319 · one of two readings recorded this
LDL cholesterol fall
decreases, p = 0.001
SH administration was associated with a 10.5% +/- 9.4% and a 20.1% +/- 6.8% fall in total cholesterol (p < 0.05) and low-density Lipoprotein cholesterol (p < 0.001) in phase A
PMID 16722024 · one of two readings recorded this
LDL cholesterol fall
decreases, p = 0.001
11.9% +/- 7.2% (p < 0.05) and 21.5% +/- 2.4% (p < 0.001), respectively, in phase B
PMID 16722024 · one of two readings recorded this
reduction in serum phosphorus
no effect
by 1.18 +/- 0.07 mg/dL (0.38 +/- 0.03 mmol/L) with SH and by 1.25 +/- 0.15 mg/dL (0.40 +/- 0.05 mmol/L) with AH in phase A (p = NS)
PMID 16722024 · one of two readings recorded this
reduction in serum phosphorus
no effect
by 1.35 +/- 0.25 mg/dL (0.43 +/- 0.08 mmol/L) with AH and by 1.23 +/- 0.80 mg/dL (0.39 +/- 0.25 mmol/L) with SH in phase B (p = NS)
PMID 16722024 · one of two readings recorded this
serum lipid parameters
no effect
In both phases of the study, AH administration was not followed by a significant change in serum lipid parameters
PMID 16722024 · one of two readings recorded this
total cholesterol fall
decreases, p = 0.05
SH administration was associated with a 10.5% +/- 9.4% and a 20.1% +/- 6.8% fall in total cholesterol (p < 0.05) and low-density Lipoprotein cholesterol (p < 0.001) in phase A
PMID 16722024 · one of two readings recorded this
total cholesterol fall
decreases, p = 0.05
11.9% +/- 7.2% (p < 0.05) and 21.5% +/- 2.4% (p < 0.001), respectively, in phase B
PMID 16722024 · one of two readings recorded this
association of iFGF23 with serum Pi
decreases
negative association was detected between iFGF23 and serum Pi, whereas positive association was observed between iPTH and serum Pi during the short period
PMID 17063170 · one of two readings recorded this
association of iPTH with serum Pi
increases
negative association was detected between iFGF23 and serum Pi, whereas positive association was observed between iPTH and serum Pi during the short period
PMID 17063170 · one of two readings recorded this
postprandial serum inorganic phosphate, intact FGF23, intact PTH, 1,25-dihydroxyvitamin D and calcium, and urinary Pi and Ca excretion up to 8 h after test meals containing 400, 800 or 1200 mg Pi
increases
Not recorded as a finding: the comparison was against another active treatment
Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake.
PMID 17063170 · one of two readings recorded this
postprandial serum inorganic phosphate (Pi) and intact FGF23, urinary Pi excretion, up to 8 h after lunch containing 400, 800 or 1200 mg Pi
increases
Not recorded as a finding: the comparison was against another active treatment
Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake.
PMID 17063170 · one of two readings recorded this
serum iFGF23 level
increases
Significant increase of iFGF23 was observed at 8 h after P1200 intake compared with both P400 and P800 intake
PMID 17063170 · one of two readings recorded this
serum iFGF23 level
no effect
Serum iFGF23 levels slightly decreased up to 8 h after P400 intake and up to 6 h after P800 intake, but not changed in P1200 intake
PMID 17063170 · one of two readings recorded this
serum iFGF23 level
decreases
Serum iFGF23 levels slightly decreased up to 8 h after P400 intake and up to 6 h after P800 intake, but not changed in P1200 intake
PMID 17063170 · one of two readings recorded this
serum iFGF23 level
decreases
Serum iFGF23 levels slightly decreased up to 8 h after P400 intake and up to 6 h after P800 intake, but not changed in P1200 intake
PMID 17063170 · one of two readings recorded this
serum iPTH level
increases
Serum iPTH levels at 1-2 and 4-6 h after P1200 intake was significantly higher than those of P400 intake
PMID 17063170 · one of two readings recorded this
serum Pi level
increases
Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake
PMID 17063170 · one of two readings recorded this
serum Pi level
increases
Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake
PMID 17063170 · one of two readings recorded this
urinary Pi excretion
increases
Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake
PMID 17063170 · one of two readings recorded this
urinary Pi excretion
increases
Serum Pi levels and urinary Pi excretion significantly increased within 1 h after P400 and P800 intake
PMID 17063170 · one of two readings recorded this
blood lactate concentration
no effect, n = 6
Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading
PMID 17569583 · one of two readings recorded this
heart rate, minute ventilation, RER and blood lactate concentration during the time trial
no effect
Not recorded as a finding: no outcome nodes for these measures; the sentence names SP only in an agentless passive
Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading.
PMID 17569583 · one of two readings recorded this
heart rate
no effect, n = 6
Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading
PMID 17569583 · one of two readings recorded this
mean power during 16.1 km time-trial
increases, p = 0.05, n = 6
After SP loading mean power was greater than for P and C (C, 322+/-15 W; P, 317+/-16 W; SP, 347+/-19 W; ANOVA, P<0.05)
PMID 17569583 · one of two readings recorded this
mean power output over a self-paced 16.1 km time trial
increases
Not recorded as a finding: mean-power-output node is a fixed-duration maximal effort (Wingate type); a variable-duration self-paced trial is a near miss for that definition
After SP loading mean power was greater than for P and C (C, 322+/-15 W; P, 317+/-16 W; SP, 347+/-19 W; ANOVA, P<0.05) and time to complete the 16.1 km was shorter than P, but not C (ANOVA, P<0.05).
PMID 17569583 · one of two readings recorded this
mean power output, relative change SP versus P
increases, n = 6
mean changes were mean power output +9.8+/-8.0% (+/-95% confidence interval); time -3.0+/-2.9%
PMID 17569583 · one of two readings recorded this
minute ventilation (V (E))
no effect, n = 6
Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading
PMID 17569583 · one of two readings recorded this
oxygen uptake (V O(2))
unclear, p = 0.07, n = 6
There was a tendency towards higher V O(2) after SP loading (ANOVA, P = 0.07)
PMID 17569583 · one of two readings recorded this
respiratory exchange ratio (RER)
no effect, n = 6
Heart rate, V (E), RER and blood lactate concentration were not significantly affected by SP loading
PMID 17569583 · one of two readings recorded this
time to complete 16.1 km, relative change SP versus P
decreases, n = 6
mean changes were mean power output +9.8+/-8.0% (+/-95% confidence interval); time -3.0+/-2.9%
PMID 17569583 · one of two readings recorded this
time to complete 16.1 km
decreases, p = 0.05, n = 6
time to complete the 16.1 km was shorter than P, but not C (ANOVA, P<0.05)
PMID 17569583 · one of two readings recorded this
time to complete a laboratory 16.1 km cycling time trial, and mean power output over it, after tribasic dodecahydrate sodium phosphate 1 g four times daily for 6 days against lactose placebo and an unsupplemented control trial
decreases
Not recorded as a finding: the supporting sentence never names the compound
After SP loading mean power was greater than for P and C (C, 322+/-15 W; P, 317+/-16 W; SP, 347+/-19 W; ANOVA, P<0.05) and time to complete the 16.1 km was shorter than P, but not C (ANOVA, P<0.05).
PMID 17569583 · one of two readings recorded this
24-h urinary phosphate excretion reduction
no effect
but the difference compared with placebo did not reach significance (64% vs. 31%)
PMID 20631407 · one of two readings recorded this
24-h urinary phosphate excretion reduction
decreases, p = 0.0001
Compared with the 1500-mg phosphorus diet, patients assigned to the 750-mg diet had greater reduction in 24-h urinary phosphate excretion (66% vs. 29%; P<0.0001)
PMID 20631407 · one of two readings recorded this
24-h urinary phosphate excretion reduction
decreases, p = 0.0001
Lanthanum-treated patients experienced a significant reduction in 24-h urinary phosphate excretion compared with baseline (64%; P<0.0001)
PMID 20631407 · one of two readings recorded this
FGF23 levels
increases
FGF23 levels actually increased significantly in the 1500-mg diet plus placebo group
PMID 20631407 · one of two readings recorded this
FGF23 levels
no effect
no group demonstrated a significant reduction in FGF23 levels
PMID 20631407 · one of two readings recorded this
energy intake at laboratory meal, prolonged supplementation
no effect, p = 0.581
or prolonged supplementation with sodium phosphate (p = .581) compared with placebo
PMID 22804972 · one of two readings recorded this
energy intake at laboratory meal
no effect, p = 0.385
no difference in energy intake at the laboratory meal after an acute dose (i.e., on Day 1; placebo 2,471 ± 919 kJ, phosphate 2,353 ± 987 kJ; p = .385)
PMID 22804972 · one of two readings recorded this
VO(2peak)
no effect, p = 0.483
no difference in VO(2peak) with phosphate supplementation (placebo 52.6 ± 5.2 ml · kg(-1) · min(-1), phosphate 53.3 ± 6.1 ml · kg(-1) · min(-1); p = .483)
PMID 22804972 · one of two readings recorded this
maximal oxygen uptake
increases, n = 7
Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1
PMID 2355823 · one of two readings recorded this
hemoglobin
increases, n = 7
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion
PMID 2355823 · one of two readings recorded this
2,3-diphosphoglycerate
decreases, n = 7
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion
PMID 2355823 · one of two readings recorded this
2,3-diphosphoglycerate
decreases, n = 7
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion
PMID 2355823 · one of two readings recorded this
5-mile run time
no effect, n = 7
Five-mile run times were nonsignificantly different between placebo and phosphate sessions
PMID 2355823 · one of two readings recorded this
blood haemoglobin, venous samples before and after max and run sessions
increases, hemoglobin values were elevated with phosphate ingestion
Not recorded as a finding: blood-haemoglobin node exists but the sentence gives no significance statement and pools resting and post-exercise values in one sentence with 2,3-DPG; direction not anchored as a tested between-arm result
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.
PMID 2355823 · one of two readings recorded this
blood hemoglobin, resting and post-exercise, method not stated
increases
Not recorded as a finding: node blood-haemoglobin exists but the sentence states no significance and no method, and shares the sentence with 2,3-DPG; left out rather than claim an unqualified increase
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.
PMID 2355823 · one of two readings recorded this
mean oxygen uptake during the 5-mile performance run
decreases, 3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1, significantly lower
Not recorded as a finding: no_outcome_node: submaximal run oxygen uptake (running economy) has no outcome
However, mean performance run oxygen uptake was significantly lower (3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1) with phosphate ingestion.
PMID 2355823 · one of two readings recorded this
oxygen uptake during 5-mile performance run
decreases, n = 7
mean performance run oxygen uptake was significantly lower (3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1) with phosphate ingestion
PMID 2355823 · one of two readings recorded this
oxygen uptake during the 5-mile performance run, l.min-1
decreases, from 3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1, n = 7
Not recorded as a finding: submaximal run oxygen cost, not VO2max; no outcome node
However, mean performance run oxygen uptake was significantly lower (3.87 +/- 0.3 to 3.80 +/- 0.3 l.min-1) with phosphate ingestion.
PMID 2355823 · one of two readings recorded this
red cell 2,3-diphosphoglycerate, resting and post-exercise
decreases
Not recorded as a finding: no outcome node for 2,3-diphosphoglycerate; sentence is also agentless about arms beyond 'phosphate ingestion' and gives no estimate
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.
PMID 2355823 · one of two readings recorded this
serum 2,3-diphosphoglycerate, resting and post-exercise
decreases, values were decreased with phosphate ingestion
Not recorded as a finding: no_outcome_node: no outcome for red cell or serum 2,3-diphosphoglycerate
Resting and post-exercise 2,3-diphosphoglycerate values were decreased while hemoglobin values were elevated with phosphate ingestion.
PMID 2355823 · one of two readings recorded this
serum phosphate, resting and post-exercise, assay not stated
increases
Not recorded as a finding: node serum-phosphate requires a colorimetric molybdate assay the abstract never states; also a manipulation check of the dosed compound
Results revealed that placebo resting serum phosphate levels were mildly elevated and that phosphate loading significantly increased resting and post-exercise serum phosphate values.
PMID 2355823 · one of two readings recorded this
serum phosphate, resting and post-exercise
increases, significantly increased resting and post-exercise serum phosphate values
Not recorded as a finding: no_outcome_node: no outcome for serum phosphate concentration
Results revealed that placebo resting serum phosphate levels were mildly elevated and that phosphate loading significantly increased resting and post-exercise serum phosphate values.
PMID 2355823 · one of two readings recorded this
serum phosphate
increases, n = 7
phosphate loading significantly increased resting and post-exercise serum phosphate values
PMID 2355823 · one of two readings recorded this
serum phosphate
increases, n = 7
phosphate loading significantly increased resting and post-exercise serum phosphate values
PMID 2355823 · one of two readings recorded this
serum phosphate
unclear, n = 7
placebo resting serum phosphate levels were mildly elevated
PMID 2355823 · one of two readings recorded this
ventilatory anaerobic threshold, l.min-1 oxygen uptake during maximal running test
increases, from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1
Not recorded as a finding: no_outcome_node: no outcome for ventilatory anaerobic threshold
Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1.
PMID 2355823 · one of two readings recorded this
ventilatory anaerobic threshold, l.min-1
increases, from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1, n = 7
Not recorded as a finding: no outcome node for ventilatory anaerobic threshold
Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1.
PMID 2355823 · one of two readings recorded this
ventilatory anaerobic threshold
increases, n = 7
Phosphate loading significantly increased maximal oxygen uptake from 4.77 +/- 0.29 to 5.18 +/- 0.25 l.min-1 and ventilatory anaerobic threshold from 3.74 +/- 0.28 to 4.18 +/- 0.14 l.min-1
PMID 2355823 · one of two readings recorded this
postprandial apolipoprotein B100
decreases, p = 0.05
phosphorus supplementation increased postprandial concentrations of apolipoprotein B48 (ApoB48) (p<0.05) and decreased that of apolipoprotein B100 (ApoB100) (p<0.05)
PMID 25002136 · one of two readings recorded this
postprandial apolipoprotein B48
increases, p = 0.05
phosphorus supplementation increased postprandial concentrations of apolipoprotein B48 (ApoB48) (p<0.05) and decreased that of apolipoprotein B100 (ApoB100) (p<0.05)
PMID 25002136 · one of two readings recorded this
postprandial insulin, NEFA and triglyceride
no effect
In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo
PMID 25002136 · one of two readings recorded this
postprandial serum phosphorus
increases
In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo
PMID 25002136 · one of two readings recorded this
postprandial triglyceride, 6-hour repeated-measures ANOVA, no fast-state sample
no effect, not significantly different than placebo
Not recorded as a finding: serum-triglycerides node requires a sample after a stated fast; this is postprandial, a near miss
In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo.
PMID 25002136 · one of two readings recorded this
postprandial triglyceride, NEFA, insulin, ApoB48 and ApoB100 over 6 hours after a high-fat meal with 500 mg phosphorus or placebo
no effect
Not recorded as a finding: a node exists but the paper states a different instrument or population
In the phosphorus (P) supplemented group, postprandial serum P increased (p=0.00), while changes in insulin, non-esterified fatty acids (NEFA) and triglyceride (TG) were not significantly different than that of placebo.
PMID 25002136 · one of two readings recorded this
mean power output in repeated-sprint test
increases, p = 0.05
the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)
PMID 25494032 · one of two readings recorded this
mean power output in repeated-sprint test
increases, p = 0.05
the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)
PMID 25494032 · one of two readings recorded this
mean power output in time-trial test
increases
time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading
PMID 25494032 · one of two readings recorded this
mean power output in time-trial test
increases
time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading
PMID 25494032 · one of two readings recorded this
power output
no effect, p = 0.05
In the placebo group, no differences (P > 0.05) in total work or power output were noted in response to supplementation
PMID 25494032 · one of two readings recorded this
total work
no effect, p = 0.05
In the placebo group, no differences (P > 0.05) in total work or power output were noted in response to supplementation
PMID 25494032 · one of two readings recorded this
work and mean power output in repeated 15 s sprints and 5 min time-trial efforts on an air-braked cycle ergometer, change from baseline at day 1 and day 4 post-loading
increases
Not recorded as a finding: the result compares a group with itself, not with a control
Compared with baseline, the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W) and time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading.
PMID 25494032 · one of two readings recorded this
work and mean power output in repeated-sprint (4 sets of 6 x 15 s) and time-trial (2 x 5 min) cycling efforts on an air-braked ergometer, 1 and 4 days post-loading
increases, work and mean power higher than baseline in the sodium phosphate group, e.g. sprint 719 W to 754 W on day 1
Not recorded as a finding: the result compares a group with itself, not with a control
Compared with baseline, the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W) and time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading.
PMID 25494032 · one of two readings recorded this
work in repeated-sprint test
increases, p = 0.05
the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)
PMID 25494032 · one of two readings recorded this
work in repeated-sprint test
increases, p = 0.05
the sodium phosphate group recorded significantly improved (P < 0.05) work and mean power output values in both the sprint (baseline, 259 kJ/719 W; day 1, 271 kJ/754 W; day 4, 271 kJ/753 W)
PMID 25494032 · one of two readings recorded this
work in time-trial test
increases
time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading
PMID 25494032 · one of two readings recorded this
work in time-trial test
increases
time-trial (baseline, 225 kJ/374 W; day 1, 235 kJ/398 W; day 4, 236 kJ/393 W) aspects of the performance test post-loading
PMID 25494032 · one of two readings recorded this
best sprint time, all sets
decreases, p = 0.01
best sprints were 0.13-0.23 and 0.15-0.20 s faster (~6% improvement; p < 0.01) after SP compared with placebo and BJ, respectively, for all sets
PMID 26077126 · one of two readings recorded this
best sprint time, all sets
decreases, p = 0.01
best sprints were 0.13-0.23 and 0.15-0.20 s faster (~6% improvement; p < 0.01) after SP compared with placebo and BJ, respectively, for all sets
PMID 26077126 · one of two readings recorded this
total and best sprint time in 6 x 20-m repeated-sprint sets of a simulated team-game circuit
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Specifically, total and best sprint times were faster after SP compared with placebo and BJ.
PMID 26077126 · one of two readings recorded this
total and best sprint times of 6 x 20-m repeated-sprint sets at the start, half-time and end of a simulated team-game circuit
decreases
Not recorded as a finding: a node exists but the paper states a different instrument or population
Specifically, total and best sprint times were faster after SP compared with placebo and BJ.
PMID 26077126 · one of two readings recorded this
total sprint time, overall across repeated-sprint sets
decreases, p = 0.02
3.25 and 3.12 s faster overall (~5% improvement) after SP compared with placebo and BJ, respectively (p = 0.02 for sets 1, 2 and overall
PMID 26077126 · one of two readings recorded this
total sprint time, overall across repeated-sprint sets
decreases, p = 0.02
3.25 and 3.12 s faster overall (~5% improvement) after SP compared with placebo and BJ, respectively (p = 0.02 for sets 1, 2 and overall
PMID 26077126 · one of two readings recorded this
total sprint time, repeated-sprint set 2
decreases, p = 0.05
total sprint times were 0.48 s faster after SP + BJ compared with placebo (set 2; p = 0.05, ~2% improvement)
PMID 26077126 · one of two readings recorded this
baseline age
n = 26
The mean age was 36.67 (9.76) years in the placebo group and 34.04 (11.24) years in the phosphorus group
PMID 26690287 · one of two readings recorded this
baseline age
n = 21
The mean age was 36.67 (9.76) years in the placebo group and 34.04 (11.24) years in the phosphorus group
PMID 26690287 · one of two readings recorded this
baseline glomerular filtration rate
n = 26
a mean of 114.14 (10.19) ml min−1 per 1.73 m2 and 112.24 (13.46) ml min−1 per 1.73 m2 for the placebo and phosphorus groups, respectively
PMID 26690287 · one of two readings recorded this
baseline glomerular filtration rate
n = 21
a mean of 114.14 (10.19) ml min−1 per 1.73 m2 and 112.24 (13.46) ml min−1 per 1.73 m2 for the placebo and phosphorus groups, respectively
PMID 26690287 · one of two readings recorded this
BMI, between-group difference in change
decreases, p = 0.01, n = 47
the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12)
PMID 26690287 · one of two readings recorded this
BMI, change from baseline
decreases, n = 26
the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12)
PMID 26690287 · one of two readings recorded this
BMI, change from baseline
increases, n = 21
the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12)
PMID 26690287 · one of two readings recorded this
body mass index change over 12 weeks, from measured weight and height
BMI change placebo 0.42 vs phosphorus -0.24 kg/m2, significantly different, p = 0.01
Not recorded as a finding: the sentence gives no direction in words; the arm changes are signed estimates only
Consequently, the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12).
PMID 26690287 · one of two readings recorded this
body mass index from measured height and weight, change from baseline to 12 weeks
placebo +0.42 kg/m2 (95% CI 0.05 to 0.78) against phosphorus -0.24 kg/m2 (95% CI -0.59 to 0.12), p = 0.01
Not recorded as a finding: Direction is carried only as signed estimates, 'significantly different' with no direction word
Consequently, the changes in BMI of the placebo group (0.42 kg m−2, 95% CI 0.05 to 0.78) was significantly different (P=0.01) than that of the phosphorus group (−0.24 kg m−2, 95% CI −0.59 to 0.12).
PMID 26690287 · one of two readings recorded this
body weight, between-group difference in change
decreases, p = 0.01, n = 47
These variations resulted in a significant difference (P=0.01) in the changes in body weight between the two groups
PMID 26690287 · one of two readings recorded this
body weight, change from baseline
decreases, n = 26
that of the phosphorus group decreased by 0.65 kg (95% CI −1.69 to 0.40)
PMID 26690287 · one of two readings recorded this
body weight, change from baseline
increases, n = 21
Body weight of the placebo group increased significantly from baseline by 1.13 kg (95% confidence interval (CI) 0.19 to 2.06)
PMID 26690287 · one of two readings recorded this
body weight change over 12 weeks, calibrated Seca balance
between-group difference in body-weight change significant, p = 0.01
Not recorded as a finding: the between-group sentence says only that the difference was significant and names neither the compound nor a direction; the sentence naming the direction describes two within-arm changes, one of them non-significant
These variations resulted in a significant difference (P=0.01) in the changes in body weight between the two groups.
PMID 26690287 · one of two readings recorded this
body weight on a calibrated Seca balance, change from baseline to 12 weeks
decreases, phosphorus group -0.65 kg (95% CI -1.69 to 0.40) against placebo +1.13 kg (95% CI 0.19 to 2.06)
Not recorded as a finding: The only sentence naming the phosphorus group reports a within-arm change; the between-group contrast is in the next sentence, which does not name the compound
Body weight of the placebo group increased significantly from baseline by 1.13 kg (95% confidence interval (CI) 0.19 to 2.06), whereas that of the phosphorus group decreased by 0.65 kg (95% CI −1.69 to 0.40).
PMID 26690287 · one of two readings recorded this
HOMA-IR, change
unclear, n = 47
Serum levels of insulin and HOMA-IR were similar between the two treatments at baseline and at 12 weeks, although a mild but significant difference was detected in their changes
PMID 26690287 · one of two readings recorded this
hunger, change
decreases, n = 47
The changes in several parameters of subjective appetite scores were found to decrease as the experiment progressed including that of appetite, quantity of food to reach fullness, hunger and number of snacks
PMID 26690287 · one of two readings recorded this
number of snacks, change
decreases, n = 47
changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo
PMID 26690287 · one of two readings recorded this
quantity of food to reach fullness, change
decreases, n = 47
changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo
PMID 26690287 · one of two readings recorded this
serum C-reactive protein
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
serum glucose
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
serum HDL cholesterol
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
serum insulin, change
unclear, n = 47
Serum levels of insulin and HOMA-IR were similar between the two treatments at baseline and at 12 weeks, although a mild but significant difference was detected in their changes
PMID 26690287 · one of two readings recorded this
serum LDL cholesterol
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
serum phosphorus, total cholesterol, LDL, HDL, triglyceride, glucose and C-reactive protein (Vitros 350), change over 12 weeks
no effect, no estimate stated
Not recorded as a finding: One sentence covers both treatments as a within-arm statement; it is not a between-arm contrast
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein.
PMID 26690287 · one of two readings recorded this
serum phosphorus, total, LDL and HDL cholesterol, triglyceride, glucose and C-reactive protein, Vitros 350 analyser, fasting, 12 weeks
no effect
Not recorded as a finding: one sentence names both arms together and reports no effect of each treatment, not a between-arm contrast, and covers seven endpoints at once, so it cannot anchor one claim
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein.
PMID 26690287 · one of two readings recorded this
serum phosphorus
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
serum total cholesterol
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
serum triglyceride
no effect, n = 47
Placebo or phosphorus treatment for 12 weeks did not affect serum levels of phosphorus, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, glucose and C-reactive protein
PMID 26690287 · one of two readings recorded this
subjective appetite, change
decreases, n = 47
changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo
PMID 26690287 · one of two readings recorded this
subjective appetite questionnaire scores (appetite, quantity of food to reach fullness, taste of food, number of snacks), questionnaire after Wilson et al.
decreases
Not recorded as a finding: no outcome node for a subjective appetite questionnaire
However, changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo as shown in Table 3.
PMID 26690287 · one of two readings recorded this
subjective appetite scores (appetite, quantity of food to reach fullness, taste of food, number of snacks), questionnaire after Wilson et al.
decreases, significantly reduced in the phosphorus group against placebo (Table 3)
Not recorded as a finding: No node for a subjective appetite questionnaire score
However, changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo as shown in Table 3.
PMID 26690287 · one of two readings recorded this
taste of food, change
decreases, n = 47
changes in appetite, quantity of food to reach fullness, taste of food and number of snacks were significantly reduced in the phosphorus group as compared with the placebo
PMID 26690287 · one of two readings recorded this
waist circumference, between-group difference in change
decreases, p = 0.001, n = 47
waist circumference of the phosphorus group was significantly reduced by 3.62 cm (95% CI −4.90 to −2.33), and this reduction was significantly different (P<0.001) from the small increase of 0.38 cm (95% CI −0.44 to 1.20) in the waist circumference of the placebo group
PMID 26690287 · one of two readings recorded this
waist circumference, change from baseline
decreases, n = 26
waist circumference of the phosphorus group was significantly reduced by 3.62 cm (95% CI −4.90 to −2.33), and this reduction was significantly different (P<0.001) from the small increase of 0.38 cm (95% CI −0.44 to 1.20) in the waist circumference of the placebo group
PMID 26690287 · one of two readings recorded this
waist circumference, change from baseline
no effect, n = 21
waist circumference of the phosphorus group was significantly reduced by 3.62 cm (95% CI −4.90 to −2.33), and this reduction was significantly different (P<0.001) from the small increase of 0.38 cm (95% CI −0.44 to 1.20) in the waist circumference of the placebo group
PMID 26690287 · one of two readings recorded this
Acetivibrio genus and Coriobacteriaceae family abundance
decreases, p = 0.05
Abundance of the genus Acetivibio and of the family Coriobacteriaceae were significantly lower in men after eight weeks of P1000/Ca500 intervention when compared to P1000/Ca0 intervention (p < 0.05)
PMID 29452584 · one of two readings recorded this
Bifidobacterium OTU abundance
decreases, p = 0.04
The OTUs belonging to Bifidobacterium genus were significantly less abundant in faeces of men of the P1000/Ca1000 intervention compared to the faeces of men of the P1000/Ca500 group (p = 0.04)
PMID 29452584 · one of two readings recorded this
Clostridium XVIII abundance
increases, p = 0.04
Clostridium XVIII was significantly more abundant in men of the P1000/Ca1000 intervention group compared to men of the P1000/Ca500 (p = 0.04) and P1000/Ca0 (p = 0.04) groups
PMID 29452584 · one of two readings recorded this
Clostridium XVIII abundance
increases, p = 0.04
Clostridium XVIII was significantly more abundant in men of the P1000/Ca1000 intervention group compared to men of the P1000/Ca500 (p = 0.04) and P1000/Ca0 (p = 0.04) groups
PMID 29452584 · one of two readings recorded this
faecal fat
no effect
8 weeks | 5.5 ± 3.1 | 5.6 ± 2.5 | 4.0 ± 2.3
PMID 29452584 · one of two readings recorded this
faecal fat
Placebo | 5.9 ± 2.8 | 5.6 ± 3.2 | 4.1 ± 1.7
PMID 29452584 · one of two readings recorded this
faecal pH value
decreases
In the whole study collective and in male subjects, the pH value decreased significantly due to P1000/Ca1000 intervention after eight weeks compared to placebo
PMID 29452584 · one of two readings recorded this
faecal pH value
decreases
8 weeks | 6.5 ± 0.5 | 6.3 ± 0.5 | 6.5* ± 0.6
PMID 29452584 · one of two readings recorded this
faecal pH value
Placebo | 6.7 ± 0.7 | 6.6 ± 0.5 | 7.0 ± 0.7
PMID 29452584 · one of two readings recorded this
faecal short-chain fatty acids (total SCFA, acetate) by gas chromatography, faecal fat by Soxhlet extraction, faecal water cyto- and genotoxicity in HT29 cells
no effect
Not recorded as a finding: this platform holds no node for the endpoint
Faecal fat concentrations did not change significantly due to the interventions (Table 1).
PMID 29452584 · one of two readings recorded this
faecal water genotoxic activity before intervention
increases
FW obtained from P1000/Ca0 subjects showed significantly higher genotoxic activity before the intervention compared to those from the P1000/Ca1000 group
PMID 29452584 · one of two readings recorded this
genotoxic activity of faecal water (tail intensity)
no effect
The interventions with phosphorus did not significantly affect the TI as a marker for genotoxic activity of the FW
PMID 29452584 · one of two readings recorded this
gut microbial community structure (Bray-Curtis)
modulates, p = 0.01
men of the P1000/Ca1000 intervention had a significantly different gut microbial community compared to the men of the P1000/Ca0 (R = 0.778, p = 0.01) and the P1000/Ca500 groups (R = 0.593, p = 0.01)
PMID 29452584 · one of two readings recorded this
gut microbial community structure (Bray-Curtis)
modulates, p = 0.01
men of the P1000/Ca1000 intervention had a significantly different gut microbial community compared to the men of the P1000/Ca0 (R = 0.778, p = 0.01) and the P1000/Ca500 groups (R = 0.593, p = 0.01)
PMID 29452584 · one of two readings recorded this
HT29 cell vitality after faecal water incubation
After incubation with FW, vitality of the HT29 cells ranged on average between 73 and 83%
PMID 29452584 · one of two readings recorded this
HT29 cell vitality after faecal water incubation
increases
For the P1000/Ca1000 intervention group, incubation of HT29 cells with FW from the eight-week time-point resulted in a significantly higher vitality of the cells compared to placebo
PMID 29452584 · one of two readings recorded this
OTU2 (butyrate-producing bacterium) abundance
increases, p = 0.01
OTU2, a butyrate-producing bacterium, was significantly more abundant in men of the P1000/Ca0 intervention group compared to the men with P1000/Ca1000 supplementation (p = 0.01)
PMID 29452584 · one of two readings recorded this
OTU4 (Clostridium XVIII-related) abundance
increases, p = 0.04
OTU4, an uncultured bacterium related to Clostridium XVIII, was significantly more abundant in the men of P1000/Ca1000 intervention group compared to P1000/Ca500 (p = 0.03) and P1000/Ca0 (p = 0.04)
PMID 29452584 · one of two readings recorded this
OTU4 (Clostridium XVIII-related) abundance
increases, p = 0.03
OTU4, an uncultured bacterium related to Clostridium XVIII, was significantly more abundant in the men of P1000/Ca1000 intervention group compared to P1000/Ca500 (p = 0.03) and P1000/Ca0 (p = 0.04)
PMID 29452584 · one of two readings recorded this
tail intensity, negative control
PBS (negative control) caused no genotoxic damages (TI 7 ± 2%)
PMID 29452584 · one of two readings recorded this
tail intensity of faecal water
mean TI for all subjects 25 ± 13%
PMID 29452584 · one of two readings recorded this
tail intensity, positive control
H2O2 caused strong genotoxic effects (TI 59 ± 15%)
PMID 29452584 · one of two readings recorded this
total SCFA, acetate, propionate and butyrate
no effect
Considering men and women together, the interventions did not affect the concentrations of total SCFA or the concentrations of the main SCFA acetate, propionate and butyrate compared to placebo
PMID 29452584 · one of two readings recorded this
total short-chain fatty acids and acetate
increases
acetate and total SCFA concentrations were significantly higher in the P1000/Ca1000 group compared to the P1000/Ca0 group after eight weeks, but only in male subjects
PMID 29452584 · one of two readings recorded this
total short-chain fatty acids and acetate
increases
Certainly, concentrations of total SCFA and acetate were significantly higher after eight weeks of P1000/Ca500 supplementation compared to the P1000/Ca0
PMID 29452584 · one of two readings recorded this
20 km time-trial completion time
no effect, n = 20
There were also no effects of supplementation on time-trial performance (placebo: 32.8 ± 2.2 min; SP: 32.8 ± 2.3 min)
PMID 29985679 · one of two readings recorded this
minute ventilation during the 20 km time trial, expired-air monitoring
increases, mean difference 3.81 L/min, 95% CI 0.16 to 7.46
Not recorded as a finding: no outcome node for minute ventilation
Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).
PMID 29985679 · one of two readings recorded this
minute ventilation (VE) during time trial
increases, n = 20
(mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1])
PMID 29985679 · one of two readings recorded this
physiological responses during submaximal cycling at 65% VO2max (VO2, VE, RER, heart rate, RPE, lactate)
no effect, p = 0.05, n = 20
There were no effects (p ≥ .05) of supplementation on physiological responses during cycling
PMID 29985679 · one of two readings recorded this
post time-trial blood lactate concentration, capillary sample
increases, mean difference 1.06 mmol/L, 95% CI 0.31 to 1.80
Not recorded as a finding: no outcome node for blood lactate concentration
Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).
PMID 29985679 · one of two readings recorded this
post time-trial blood lactate concentration
increases, n = 20
blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1])
PMID 29985679 · one of two readings recorded this
rating of perceived exertion (RPE) during time trial
increases, n = 20
(mean difference: 0.39; 95% confidence interval: [0.04, 0.73])
PMID 29985679 · one of two readings recorded this
ratings of perceived exertion (RPE) during a 20 km cycling time trial; also 20 km time-trial completion time, minute ventilation, RER and post time-trial blood lactate
increases, RPE mean difference 0.39, 95% CI [0.04, 0.73], SP relative to placebo
Not recorded as a finding: the supporting sentence never names the compound
Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).
PMID 29985679 · one of two readings recorded this
respiratory exchange ratio during the 20 km time trial
increases, mean difference 0.020, 95% CI 0.004 to 0.036
Not recorded as a finding: no outcome node for respiratory exchange ratio
Nevertheless, relative to placebo, SP increased V̇E (mean difference: 3.81 L·min-1; 95% confidence interval: [0.16, 7.46 L·min-1]), RER (mean difference: 0.020; 95% confidence interval: [0.004, 0.036]), and RPE (mean difference: 0.39; 95% confidence interval: [0.04, 0.73]) during time trials, as well as post time-trial blood lactate concentration (mean difference: 1.06 mmol·L-1; 95% confidence interval: [0.31, 1.80 mmol·L-1]).
PMID 29985679 · one of two readings recorded this
respiratory exchange ratio (RER) during time trial
increases, n = 20
(mean difference: 0.020; 95% confidence interval: [0.004, 0.036])
PMID 29985679 · one of two readings recorded this
postprandial energy expenditure and substrate oxidation, ventilated hood indirect calorimetry for 240 min
increases
Not recorded as a finding: this platform holds no node for the endpoint
Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001), although in different patterns.
PMID 30153580 · one of two readings recorded this
postprandial energy expenditure over 240 min, ventilated hood indirect calorimetry
increases
Not recorded as a finding: this platform holds no node for the endpoint
Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001), although in different patterns.
PMID 30153580 · one of two readings recorded this
postprandial energy expenditure
increases, p = 0.001, n = 8
Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001)
PMID 30153580 · one of two readings recorded this
postprandial energy expenditure
increases, p = 0.001, n = 7
Phosphorus ingestion with a meal increased the postprandial energy expenditure of both lean and obese individuals (P < 0.001)
PMID 30153580 · one of two readings recorded this
respiratory quotient
decreases, n = 8
Alterations in postprandial substrate oxidation was highly noticeable from time 120 min onward, where phosphorus-treated lean participants exhibited a significant decrease in respiratory quotient
PMID 30153580 · one of two readings recorded this
postprandial energy expenditure and substrate oxidation every 30 min for 4 h, ventilated hood indirect calorimetry
increases, p = 0.005
Not recorded as a finding: this platform holds no node for the endpoint
NPr and HPr meals had similar postprandial energy expenditure and this was significantly increased (P = 0.005) by P ingestion.
PMID 30509638 · one of two readings recorded this
postprandial energy expenditure every 30 min for 4 h, ventilated hood indirect calorimetry
increases, p = 0.005
Not recorded as a finding: this platform holds no node for the endpoint
NPr and HPr meals had similar postprandial energy expenditure and this was significantly increased (P = 0.005) by P ingestion.
PMID 30509638 · one of two readings recorded this
postprandial energy expenditure
increases, p = 0.005, n = 24
NPr and HPr meals had similar postprandial energy expenditure and this was significantly increased (P = 0.005) by P ingestion
PMID 30509638 · one of two readings recorded this
diastolic blood pressure
unclear
Four studies found a significant inverse association with diastolic BP and 10 no significant associations
PMID 31051505 · one of two readings recorded this
incident hypertension, highest vs lowest quintile of phosphorus intake
decreases
HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27)
PMID 31051505 · one of two readings recorded this
incident hypertension, highest vs lowest quintile of phosphorus intake
decreases
HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27)
PMID 31051505 · one of two readings recorded this
incident hypertension, highest vs lowest quintile of phosphorus intake
no effect
HR: 0.86 (95% CI: 0.75, 0.98); HR: 0.83 (95% CI: 0.68, 1.02); and HR: 0.75 (95% CI: 0.45, 1.27)
PMID 31051505 · one of two readings recorded this
systolic blood pressure
unclear
Two studies found a significant positive association of dietary phosphorus with systolic BP, 4 a significant inverse association, and 8 no significant association
PMID 31051505 · one of two readings recorded this
C-terminal fibroblast growth factor 23 (cFGF23)
no effect, n = 34
Dietary phosphorus intake was not related to cFGF23
PMID 33427559 · one of two readings recorded this
intact fibroblast growth factor 23 (iFGF23)
increases, p = 0.001, n = 34
an increase in iFGF23 of 5.0% (95% CI, 2.0-8.0, p = .001)
PMID 33427559 · one of two readings recorded this
intact parathyroid hormone (iPTH)
increases, p = 0.01, n = 34
an increase in iPTH of 5.4% (95% CI, 1.4-9.3, p = .01)
PMID 33427559 · one of two readings recorded this
serum calcium
decreases, p = 0.01, n = 34
a decrease in serum calcium of 0.06 mg/dL (95% CI, -0.11 to -0.01, p = .01)
PMID 33427559 · one of two readings recorded this
cardiac output (Q) at the given workloads
no effect, n = 20
There were no statistically significant changes in cardiac output (Q) at the given workloads (Table 2)
PMID 34684557 · one of two readings recorded this
gross efficiency at workloads below lactate threshold, work accomplished over energy expended from VO2 and RER
no effect
Not recorded as a finding: no outcome node for gross efficiency
There were no statistically significant changes in GE and RER at the given workloads after SP supplementation or placebo ingestion (Table 3).
PMID 34684557 · one of two readings recorded this
gross efficiency (GE) at the given workloads
no effect, n = 20
There were no statistically significant changes in GE and RER at the given workloads after SP supplementation or placebo ingestion (Table 3)
PMID 34684557 · one of two readings recorded this
heart rate at submaximal workloads below lactate threshold, breath-by-breath gas analyser
decreases, HR at LT-2 and LT-1 decreased 3.9% (d = 0.36) and 3.4% (d = 0.38)
Not recorded as a finding: no outcome node for submaximal heart rate
The post-hoc Tukey test showed that HRLT−2 and HRLT−1 significantly (p < 0.01) decreased due to SP supplementation by 3.9% (d = 0.36) and 3.4% (d = 0.38), respectively.
PMID 34684557 · one of two readings recorded this
hematocrit (Hct)
no effect, n = 20
There were no statistically significant changes in Hct (S1 vs. S2: SP 43.6 ± 0.6 vs. 43.1 ± 0.5%; Pl 44.1 ± 0.5 vs. 43.3 ± 0.5%)
PMID 34684557 · one of two readings recorded this
hematocrit (Hct)
no effect, n = 20
There were no statistically significant changes in Hct (S1 vs. S2: SP 43.6 ± 0.6 vs. 43.1 ± 0.5%; Pl 44.1 ± 0.5 vs. 43.3 ± 0.5%)
PMID 34684557 · one of two readings recorded this